

Secretary (OS), Department of Health and Human Services, has submitted an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB) for review and approval. The ICR is for renewal of the approved information collection assigned OMB control number 0990-0419, scheduled to expire on June 30, 2017. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public on this ICR during the review and approval period.

**DATES:** Comments on the ICR must be received on or before May 10, 2017.

**ADDRESSES:** Submit your comments to [OIRA\\_submission@omb.eop.gov](mailto:OIRA_submission@omb.eop.gov) or via facsimile to (202) 395-5806.

**FOR FURTHER INFORMATION CONTACT:** Information Collection Clearance staff, [Information.CollectionClearance@hhs.gov](mailto:Information.CollectionClearance@hhs.gov) or (202) 795-7714.

**SUPPLEMENTARY INFORMATION:** When submitting comments or requesting

information, please include the OMB control number 0990-0419 and document identifier 0990-0419-30D for reference.

**Information Collection Request Title:** Acquisition Regulation Clause Patent Rights and Rights and Data.

**Abstract:** The Department of Health and Human Services; Office of the Assistant Secretary for Financial Resources and Office of Grants and Acquisition Policy and Accountability, Division of Acquisition. is requesting an approval by OMB for an extension of a previously approved information collection request, 0990-0419—Acquisition Regulation Clause Patent rights and Rights in Data. HHS found that systematically, over a period of several years, when Determination of Exceptional Circumstances (DEC) were executed, additional legal protection for the patent and data rights of third parties beyond those covered by FAR 27.306 were necessary A DEC is executed consistent with the policy and objectives of the Bayh-Dole Act, 35

U.S.C. 200, *et. seq.*, to ensure that subject inventions made under contracts and subcontracts (at all tiers) are used in a manner to promote free competition and enterprise without unduly encumbering future research and discovery; to encourage maximum participation of small business firms in federally supported research and development efforts; to promote collaboration between commercial concerns and nonprofit organizations including universities; to ensure that the Government obtains sufficient rights in federally supported inventions to meet its needs; to protect the public against nonuse or unreasonable use of inventions; and in the case of fulfilling the mission of the U.S. Department of Health and Human Services, to ultimately to benefit the public health.

**Likely Respondents:** Administrative, technical, legal and management personnel.

The total annual burden hours estimated for this ICR are summarized in the table below.

Information collection	Type of respondent and hours for each	Number of respondents	Number of responses per respondent	Average burden per response (hours)	Total burden hours
(a) .....	Technical (4), Legal (2), Management (2) .....	63	1	8	504
(b) .....	Technical (8), Legal (2), Management (2) .....	63	1	12	756
(c) .....	Technical (8), Legal (3), Management (1) .....	63	3	12 (36)	2268
(d) .....	Technical (8), Legal (4), Management (2) .....	63	3	14 (42)	2646
(e) .....	Technical (6), Legal (2), Management (2) .....	63	1	10	630
(f) .....	Technical (4), Legal (2), Management (2) .....	63	1	8	504
(g) .....	Administrative (8) .....	63	3	8 (24)	1512
(h) .....	Administrative (2), Management (1) .....	63	3	3 (9)	567
(i) .....	Technical (4), Legal (2), Management (2) .....	63	3	8 (24)	1512
Total .....	.....	63	19	83 (173)	10,899

**Terry S. Clark,**

*Asst Information Collection Clearance Officer.*

[FR Doc. 2017-07143 Filed 4-7-17; 8:45 am]

**BILLING CODE 4150-24-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Meeting of the National Advisory Committee on Children and Disasters**

**AGENCY:** Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the National Advisory Committee on Children and Disasters (NACCD) will

hold a public teleconference on May 5, 2017.

**DATES:** The NACCD meets May 5, 2017, from 3:00 p.m. to 4:00 p.m. EST.

**ADDRESSES:** We encourage members of the public to attend the teleconference. To register, send an email under the “Contact Us” link on <https://www.phe.gov/naccd> with “NACCD Registration” in the subject line.

**FOR FURTHER INFORMATION CONTACT:** CDR Evelyn Seel, MPH at (202) 205-7960. Visit the NACCD Web site located at <https://www.phe.gov/naccd>. Please submit your comments on the NACCD Contact Form located at <https://www.phe.gov/NACCDComments>.

**SUPPLEMENTARY INFORMATION:** Pursuant to the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended), and section 2811A of the Public Health Service Act (42 U.S.C. 300hh-10a), as added by section 103 of

the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5), the HHS Secretary, in consultation with the Secretary of the U.S. Department of Homeland Security, established the NACCD. The purpose of the NACCD is to provide advice and consultation to the HHS Secretary with respect to the medical and public health needs of children in relation to disasters.

**Background:** The NACCD public teleconference on May 5, 2017, is dedicated to the deliberation and vote on two task letters from the Assistant Secretary for Preparedness and Response (ASPR). The first task letter invites the NACCD to review the role of the ASPR in future disaster preparedness and response activities that specifically affect the well-being of children. The second task letter requests the NACCD to assess progress and remaining gaps in pediatric training

needs of professionals caring for children in disasters since the 2011 National Center for Disaster Medicine and Public Health Conference on this topic. We will post modifications to the agenda on the NACCD May 5, 2017 meeting Web page, which is located at <https://www.phe.gov/naccd>.

**Availability of Materials:** We will post all meeting materials prior to the meeting on the NACCD May 5, 2017 meeting Web page located at <https://www.phe.gov/naccd>.

**Procedures for Providing Public Input:** Members of the public may attend the teleconference using a toll-free call-in phone number available on the NACCD Web site at <https://www.phe.gov/naccd>. We encourage members of the public to provide written comments that are relevant to the NACCD teleconference prior to May 5, 2017. Send written comments by email via the "Contact Us" link on <https://www.phe.gov/naccd> with "NACCD Public Comment" in the subject line. The NACCD will respond to comments received by close-of-business April 28, 2017, during the meeting.

Dated: April 4, 2017.

**George W. Korch Jr.,**

*Acting Assistant Secretary for Preparedness and Response.*

[FR Doc. 2017-07052 Filed 4-7-17; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

#### FOR FURTHER INFORMATION CONTACT:

Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact Peter Soukas at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville,

MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

#### SUPPLEMENTARY INFORMATION:

Technology description follows.

#### A Full-Length Infectious cDNA Clone of Zika Virus From the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development

**Description of Technology:** An arthropod-borne virus, Zika virus (ZIKV), has recently emerged as a major human pathogen. Associated with complications during perinatal development and Guillain-Barré syndrome in adults, ZIKV raises new challenges for understanding the molecular determinants of flavivirus pathogenesis. This underscores the necessity for the development of a reverse genetic system based on an epidemic ZIKV strain. This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin. It was observed that the growth of cDNA-derived virus was attenuated compared to the growth of the parental isolate in most cell lines, which correlates with substantial differences in sequence heterogeneity between these viruses that were determined by deep-sequencing analysis. Moreover, these results indicate that caution should be exercised when interpreting the results of reverse-genetics experiments in attempts to accurately predict the biology of natural viruses. Finally, a Vero cell-adapted cDNA clone of ZIKV was generated that can be used as a convenient platform for studies aimed at the development of ZIKV vaccines (live attenuated and inactivated) and therapeutics.

This technology is available for licensing nonexclusively in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

This technology is further described in Tsetsarkin et al., "A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development," *mBio*. 2016 Jul-Aug; 7(4): e01114-16. Published online 2016 Aug 23. doi: 10.1128/mBio.01114-16.

**Potential Commercial Applications:**

- Diagnostics
- Vaccines
- Development of therapeutics

#### Competitive Advantages:

- Use in development of flavivirus vaccines
- Virus growth in various cell lines
- Developing and developed world research tool

#### Development Stage:

- Research materials

**Inventors:** Alexander Pletnev (NIAID), Konstantin Tsetsarkin (NIAID).

**Intellectual Property:** HHS Reference No. E-114-2017/0.

**Licensing Contact:** Peter Soukas, J.D., 301-594-8730; [peter.soukas@nih.gov](mailto:peter.soukas@nih.gov).

**Collaborative Research Opportunity:** The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) or diagnostics for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301-594-8730; [peter.soukas@nih.gov](mailto:peter.soukas@nih.gov).

Dated: March 23, 2017.

**Suzanne Frisbie,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2017-07057 Filed 4-7-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

#### FOR FURTHER INFORMATION CONTACT:

Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact James M. Robinson at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and